

PROTEOME SCIENCES plc

PRESS RELEASE

For immediate release

15th March 2006

CO-MARKETING AGREEMENT FOR BIOMARKER DISCOVERY AND VALIDATION

Proteome Sciences plc (“Proteome Sciences”) and Medical Solutions plc (“Medical Solutions”) are pleased to announce that they have entered into a Co-Marketing Agreement under which the companies will work closely to promote each others’ technologies for the discovery and validation of protein biomarkers, for use in human and veterinary diagnostics and drug development programs.

The burgeoning interest in biomarker discovery, validation and implementation across human and animal healthcare has presented exciting new challenges and opportunities to provide more comprehensive technology solutions. In biomarker discovery Proteome Sciences has developed the ProteoSHOP[®] platform that combines both gel-based and gel-free protein separations to optimise the coverage of all classes of proteins and with the power to analyse complex post-translational modifications. With powerful bioinformatics and statistical algorithms ProteoSHOP[®] provides high quality biomarker candidates which are further validated using techniques such as ELISA and western blot at Proteome Sciences’ purpose built proteomics facilities in Frankfurt, Germany.

Medical Solutions has developed a suite of biomarker validation and implementation technologies for further characterising candidate biomarkers and allowing their integration into pre-clinical and clinical drug development programmes. These technologies include high throughput immunohistochemistry combined with automated image analysis incorporating proprietary feature recognition algorithms, as well as ISH and FISH. In addition to its work with the pharmaceutical and biotech industries, Medical Solutions provides routine histology and diagnostic services for the National Health Service and private practitioners. It also offers quantitative analysis to provide robust pre and post dose drug response data for use in clinical trials.

By combining the two companies’ highly complementary technologies Proteome Sciences and Medical Solutions are able to offer customers a seamless workflow from biomarker discovery through to implementation in diagnostics and drug development.

Commenting on the Co-Marketing Agreement Christopher Pearce, CEO of Proteome Sciences, said:

“We are excited to be working with Medical Solutions in the co-promotion of our respective technologies. We see considerable synergies from our existing capabilities to provide customers with a one-stop-shop for biomarker discovery and validation facilitating customers’ access and procurement of these essential technologies.”

Carol Knott, Director of Pathology Services at Medical Solutions, said:

“The alliance with Proteome Sciences will create an increased level of new business opportunities for Medical Solutions and a broader service offering for our clients. We look forward to a successful working relationship.”

Notes to editors:

Proteome Sciences plc

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity proprietary technologies to detect differentially expressed proteins in diseases. The protein biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP[®] toolbox, Proteome Sciences provides high sensitivity/high throughput proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein sequence tag technologies (PST[®], qPST[™]& TMT[®]), to major pharma, biotechnology and diagnostic companies, to discover and exploit protein biomarkers. Sensitizer[®] chemical mass tags have been developed separately as a series of stand-alone reagents.

For further information please visit www.proteomics.com.

Medical Solutions plc

Medical Solutions plc is a highly focused international healthcare business specialising in diagnostic pathology and cytology services and products. The group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities. The group also owns and operates four diagnostic pathology and cytology laboratories in Dubai, UAE. The pathology services division provides a range of expert pathology services to public/private healthcare providers and clients in the pharmaceutical/biotechnology industries. It also has access to an established bank of normal and diseased processed human tissue and a UK network of over 60 specialist consultant pathologists. The company's drug development services offerings combine expertise in laboratory diagnostics, high throughput quantitative protein expression, biomaterials resources and sophisticated image analysis techniques, providing collaborative R&D services, including biomarker assay development, to the pharmaceutical and biotechnology industry. The cytology division provides the latest cytology screening equipment and techniques, and distributes the SurePath[™] liquid based cytology system in the UK, Ireland and Middle East for both gynaecological and non-gynaecological applications.

For further information please visit www.medical-solutions.co.uk.

Enquiries:

Proteome Sciences plc

Ian Pike, Business Development Director

Email: ian.pike@proteomics.com

James Green, Commercial Director

Email: james.green@proteomics.com

Tel: +44 (0)1932 865065

Public Relations for Proteome Sciences

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 535102

Mobile: +44 (0)797 9900733

Email: adrian@ikonassociates.com

Medical Solutions plc

Jackie Rodgers, Business Development Director

Email: Jackie.Rodgers@medical-solutions.co.uk

Tel: +44 (0)7884 331645